IsoRay, Inc. (NYSEMKT:ISR) reported revenue increase during 2013 Quarter. According to the reports the company witnessed revenue earnings growth from the addition of new facilities utilizing Cesium-131, earnings from continued accrual of patients under several active studies. The company also announced FDA has cleared Liquid Cesium-131.IsoRay, Inc. (NYSEMKT:ISR) stock performance was 133.94% in last session and finished the day at $2.55. The beta of the stock remained 0.39. IsoRay, Inc. (NYSEMKT:ISR) insider ownership is 0.70%.
Geron Corporation (NASDAQ:GERN) announced that the company has received verbal notice from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for imetelstat has been placed on full clinical hold, affecting all ongoing company-sponsored clinical trials. The intra-day range of the stock was $2.21 to $2.46. Geron Corporation (NASDAQ:GERN) has a market capitalization of $353.00 million.
Synthesis Energy Systems, Inc. (NASDAQ:SYMX) announced that its wholly owned subsidiary, SES Asia Technologies, Ltd., and Zhangjiagang Chemical Machinery Co., Ltd. (“ZCM”) (Shenzhen listing code: 002564) have successfully completed a major step in the governmental approval process with the receipt of the required 20-year business license on March 18, from the State Administration for Industry & Commerce of the People’s Republic of China (SAIC) in Zhangjiagang, for the previously announced joint venture, ZCM-SES Sino-U.S. Synthesis Energy Systems, Inc. (NASDAQ:SYMX)’s total market capitalization recorded $126.16 million. The overall volume in the last trading session was 9,047,492 million shares. In its share capital, Synthesis Energy Systems, Inc. (NASDAQ:SYMX) has 126.16 63.72 million outstanding shares.
Cantor Fitzgerald lowered shares of Galena Biopharma (NASDAQ:GALE) to a sell rating in a research report released on Tuesday morning, AnalystRatingsNetwork.com reports. Galena Biopharma Inc (NASDAQ:GALE) quarterly revenue growth is -22.42%. On Wednesday, shares of Galena Biopharma Inc (NASDAQ:GALE)’s monthly performance is recorded as -18.73%.